No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ATNM Actinium
- 7.060
- +0.100+1.44%
Close Apr 24 16:00 ET
- 7.260
- +0.200+2.83%
Pre 08:08 ET
207.54MMarket Cap-3857P/E (TTM)
7.320High6.881Low153.43KVolume6.930Open6.960Pre Close1.08MTurnover0.54%Turnover RatioLossP/E (Static)29.40MShares9.86052wk High5.70P/B201.98MFloat Cap4.00052wk Low--Dividend TTM28.61MShs Float450.000Historical High--Div YieldTTM6.31%Amplitude3.000Historical Low7.067Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Actinium Says Phase 3 SIERRA Trial Results Of Iomab-B Shows Improving OS For AML Patients
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients With Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
-- Iomab-B led bone marrow transplant produced high rates of complete remission and durable complete remission regardless of TP53 mutation status in patients age 55 and above with high-risk active re
Wall Street Bulls Eye a 290% Upside on Actinium Pharmaceuticals, Inc. Amidst Groundbreaking Cancer Therapy Innovations
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM) and Centessa Pharmaceuticals (CNTA)
Actinium's Phase 3 Trial Results Show Survival Benefit In Acute Myeloid Leukemia Patients; Stock Up
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Actinium Pharmaceuticals Price Target Maintained With a $21.00/Share by Cantor Fitzgerald
Comments
$Actinium(ATNM.US$
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
Update
$Actinium(ATNM.US$ Actinium Pharmaceuticals Granted U.S. Patent #11844799: Method for Treating Cancer Using a BCL-2 Inhibitor in Conjunction With an Alpha-emitting Radioimmunotherapeutic
3
2
Update
$Actinium(ATNM.US$ Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
PR Newswire· 1 min ago
PR Newswire· 1 min ago
NO FINANCIAL DETAILS GIVEN YET?
$Actinium(ATNM.US$ Ionetix to provide Bayer with Therapeutic Radioisotope Actinium-225 (Ac-225)
3 MINUTES AGO, 6:00 AM EST
VIA PR NEWSWIRESHARE
LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225.
3 MINUTES AGO, 6:00 AM EST
VIA PR NEWSWIRESHARE
LANSING, Mich., Nov. 15, 2023 /PRNewswire/ -- Ionetix Corporation today announced the signing of a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225) with Bayer. Under the terms of the agreement, Ionetix will provide Bayer with high-purity, non-carrier added (n.c.a.) Ac-225.
Update!
$Actinium(ATNM.US$ Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg